AB Science SA is a clinical‐stage biotechnology company headquartered in Paris, France, specializing in the discovery and development of protein kinase inhibitors. The company’s lead product candidate, masitinib, is an oral tyrosine kinase inhibitor that targets key signaling pathways involved in tumor growth, inflammatory responses and neurodegenerative processes. Through selective inhibition of KIT, PDGFR and other kinases, masitinib is being evaluated in a range of serious conditions with significant unmet medical need.
AB Science’s development pipeline is anchored by multiple ongoing and completed clinical trials of masitinib. Key indications include systemic mastocytosis, amyotrophic lateral sclerosis (ALS), multiple sclerosis, metastatic pancreatic cancer and Alzheimer’s disease. The company has reported positive data from pivotal Phase III studies in systemic mastocytosis and is pursuing regulatory filings in both Europe and North America. Additional programs explore masitinib in combination with standard-of-care therapies in oncology and inflammatory disorders.
Founded in 2001, AB Science operates research and development centers in Europe and the United States. The company’s U.S. subsidiary, based in Massachusetts, supports North American clinical programs and regulatory activities. AB Science collaborates with academic institutions and biotechnology partners to advance its pipeline, leveraging a network of investigators and research sites across Europe, North America and Asia.
Under the leadership of Chief Executive Officer Bruno Lévy, AB Science remains focused on translating scientific insights into novel therapies for rare and serious diseases. The company’s strategic priorities include completing ongoing pivotal trials, expanding its clinical footprint and securing marketing approvals for masitinib in targeted indications.
AI Generated. May Contain Errors.
